New Early-Stage Genetic Toxicology Assays with Low Compound Requirements Now Available
July 13, 2010 - Genetic toxicology testing is a key element in the development of pharmaceuticals, agrochemicals and chemicals. Formal GLP testing is required as part of the safety evaluation of all compounds; however, many companies perform non-GLP genetic toxicology screening very early to avoid expensive failures later. At this point, compound availability is normally limited, so it is important to minimize usage while ensuring the most accurate predictivity of the outcome of the eventual GLP assays. Charles River now offers in vitro genetic toxicology screening assays in which compound requirements can be as little as 10 mg: Bluescreen HC, Bluescreen HC S9 and µAmes.
The Bluescreen HC and Bluescreen HC S9 assays measure up regulation of a DNA-damage stress gene (GADD45a) and the data has been shown to be highly predictive of carcinogenicity potential. The µAmes assay is conducted in 24-well plates and provides data that is highly predictive of a standard Ames test. These assays can be used to screen a number of candidate molecules simultaneously. In addition, the assays generate test results fast. Bluescreen data is available to the client within 72 hours of dosing and µAmes data within 96 hours of dosing.
For more information, please view our technical sheet or contact us at firstname.lastname@example.org.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 21–May 24
RDD Europe 2013 is a forum for pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.